Project UpdateMay 26, 2026, 11:02 AM
Alaunos ALN1003 shows favorable preclinical results in obesity mice
AI Summary
Alaunos Therapeutics reported positive integrated preclinical results for ALN1003, its investigational oral candidate for obesity and metabolic disorders. Studies in diet-induced obese mice demonstrated consistent improvements across key metabolic disease drivers, including significant reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and better liver health. The company plans further preclinical studies, formulation optimization, and manufacturing activities, but noted its cash position of $0.354 million as of March 31, 2026, with a runway into Q2 2026, necessitating additional financing.
Key Highlights
- ALN1003 reduced body weight by up to 12.9% in 48-day study and 30.5% in 18-day study.
- Fat mass decreased by 44.6% (-8.9g) in high-dose group of 18-day study.
- Liver weight reduced by 43% in 48-day study and up to 55% in 18-day study.
- Improved insulin sensitivity, lower fasting insulin, and HOMA-IR observed.
- Lower ALT, AST, ALP enzymes and qualitative anti-steatotic effect on liver histology.
- Cash and cash equivalents were $0.354 million as of March 31, 2026.
- Current cash runway extends into the second quarter of 2026.
Price Impact
More from TCRT